• News
  • General

Isis tests new heart drug

Isis Pharmaceuticals (Nasdaq: ISIS) has initiated a Phase 1 clinical study for a drug targeting apolipoprotein, which causes plaque to form on the arteries, leading to an increased risk of atherosclerosis, coronary heart disease, heart attack and stroke.

The drug, ISIS-APOARx, is designed to inhibit the body's production of apolipoprotein.


Isis publishes data supporting new treatment

Isis rings bell at Nasdaq

Isis Pharma shares rise on Kynamro approval

User Response
0 UserComments

Isis Pharmaceuticals Inc.

Company Website

1896 Rutherford Road
Carlsbad, CA 92008

Isis Pharmaceuticals Inc. Executive(s):

Stanley Crooke

  • Chairman, Chief Executive Officer, Founder, President

Similar Companies

NAICS - 325414 - Biological Product (except Diagnostic) Manufacturing